Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Transforming Medical Robotics

2,270 views

Published on

About Microbot Medical Inc.

Microbot, which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on November 28, 2016. The Company specializes in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot’s current platforms, ViRob and TipCAT, are comprised of two highly advanced micro-robotic technologies, from which the Company is currently developing its first two product candidates: the Self Cleaning Shunt, or SCS, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures. Further information about Microbot Medical is available at http://www.microbotmedical.com.

The ViRob technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the body. Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels, the digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages as well as the ability to remain within the human body for prolonged time. To learn more about ViRob please visit http://www.microbotmedical.com/technology/virob/.

TipCAT is a transformational self-propelled, flexible, and semi-disposable endoscope providing see & treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly suitable to navigate and crawl through natural & artificial tubular lumens, applying the minimal necessary pressure to achieve the adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCAT visit http://www.microbotmedical.com/technology/tipcat/.

Published in: Science
  • Be the first to comment

  • Be the first to like this

Transforming Medical Robotics

  1. 1. Transforming Medical Robotics
  2. 2. Forward Looking Statements THIS DOCUMENT IS PRIVATE AND CONFIDENTIAL, CONTAINS SENSITIVE BUSINESS INFORMATION OF MICROBOT MEDICAL INC. (“MICROBOT”) AND IS NOT FOR PUBLIC DISTRIBUTION. This document has been prepared for informational purposes only and is provided personally to you. By accepting this document you agree to keep its contents strictly confidential, not to copy any portion of this document and to return it to Microbot promptly upon its request. This document contains summary information about Microbot, does not purport to be complete, and no representations or warranties about such information are made by Microbot or its representatives. This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities of Microbot. Any such offer will be made only pursuant to an effective registration statement or an exemption from registration. This document contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, relating to future events or the future financial performance and operations of Microbot. Forward-looking statements, which involve assumptions and describe Microbot’s intent, belief or current expectations about its business opportunities, prospects, performance and results, are generally identifiable by use of the words “may,” “could,” “should,” “will,” “would,” “expect,” “anticipate,” “plan,” “potential,” “estimate,” “believe,” “intend,” “project,” “forecast,” the negative of such words and other variations on such words or similar terminology. These forward-looking statements are not guarantees of future performance and by their nature involve known and unknown risks and uncertainties that may cause actual opportunities, prospects, performance and results to vary from those presented in this document, and those variances may be material. In evaluating such statements, prospective investors should carefully consider the various risks and uncertainties identified in Microbot’s public filings with the Securities and Exchange Commission, such as market risk, liquidity risk, competitive risk, regulatory risk and other commonly recognized forms of risk relating to Microbot and its securities. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this document might not occur. Microbot is not obligated to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
  3. 3. The Medical Robotics Market Becoming Smaller, Automated, and More Precise MIS Expected to Reach >$50B Market by 2019 Applies to Most Surgical Specialties Expected >20% CAGR through 2023
  4. 4. Mazor Robotics and Medtronic Enter Next Phase of Strategic Partnership; Medtronic to Make a $40 million Third Tranche Investment in Mazor Business Wire, August 30, 2017
  5. 5. Mazor Robotics and Medtronic Enter Next Phase of Strategic Partnership; Medtronic to Make a $40 million Third Tranche Investment in Mazor Business Wire, August 30, 2017 Johnson & Johnson Announces Formation of Verb Surgical Inc., in Collaboration with Verily PR Newswire, December 10, 2015
  6. 6. Mazor Robotics and Medtronic Enter Next Phase of Strategic Partnership; Medtronic to Make a $40 million Third Tranche Investment in Mazor Business Wire, August 30, 2017 Johnson & Johnson Announces Formation of Verb Surgical Inc., in Collaboration with Verily PR Newswire, December 10, 2015 Zimmer Biomet Acquires Medtech SA, Joins Surgical Robotics Fray Med Device Online, July 20, 2016
  7. 7. Mazor Robotics and Medtronic Enter Next Phase of Strategic Partnership; Medtronic to Make a $40 million Third Tranche Investment in Mazor Business Wire, August 30, 2017 Johnson & Johnson Announces Formation of Verb Surgical Inc., in Collaboration with Verily PR Newswire, December 10, 2015 Zimmer Biomet Acquires Medtech SA, Joins Surgical Robotics Fray Med Device Online, July 20, 2016 Globus Medical Announces Acquisition of Robotics Developer KB Medical Reuters, August 2, 2017
  8. 8. Transforming vision into reality. Successfully completed the development phase of the SCS implantable component
  9. 9. Strengthening the Balance Sheet
  10. 10. Strengthening the Balance Sheet Strengthening the Intellectual Property Portfolio
  11. 11. Strengthening the Balance Sheet Strengthening the Intellectual Property Portfolio Strengthening the Lumen Surgery Technology Platforms
  12. 12. Strengthening the Balance Sheet Strengthening the Intellectual Property Portfolio Strengthening the Leadership Team Strengthening the Lumen Surgery Technology Platforms
  13. 13. The sale of STEM assets for $4 million Two separate capital market transactions totaling over $13.5 million Non-dilutive grant of ~$735,000 from the state of Israel Ministry of Economy Strengthened Balance Sheet
  14. 14. Strengthened Intellectual Property Portfolio 24 patents issued/allowed and an additional 12 patent applications pending worldwide FAMILY TITLE US PATENT/APP NO. OTHER COUNTRIES TipCAT Tip Propelled Device for Motion Through a Passage US 9,061,118 US 14/746,660 (allowed) Granted: EP (DE, FR, GB, IT), CA, JP, IN , CN (3 patents) Inflatable Chamber Device for Motion Through a Passage US 9,427,143 US 15/218,025 Granted: EP (DE, FR, GB, IT) Inflatable Balloon Device and Applications US 8,430,810 US 8,790,246 Pending: EP Multi-view Imaging System US 8,317,688 Semi-Disposable Endoscope US 8,398,540 Granted: EP (DE, FR, GB) ViRob Vibrating Robotic Crawler US 8,294,333 Granted: IL Pending: IN, CN, EP Self Cleaning Shunt US 9,393,389 US 15/187,003 Granted: CN, JP, CA Pending: EP, IN Stent for Restenosis Prevention US 9,510,959 Device for Prevention of Shunt Stenosis US 9,675,748 US 15/592,227 Pending: EP, CA, IL
  15. 15. Enter into agreement to acquire novel technology to enhance existing technology platforms Bringing unique capabilities to guidewires being used in almost every surgical space today Strengthened Lumen Surgery Technology Platforms
  16. 16. Strengthened Leadership Team Martin Madden • Former Vice President, Research & Development at Johnson & Johnson for Interventional Vascular, Global Surgery and Orthopedics Divisions • Over 30 years of extensive experience in the development of hundreds of medical projects P. (Laxmin) Laxminarain • Former Worldwide President of Codman Neurosurgery (a Johnson & Johnson company), sold to Integra Life science for over $1B in 2017 • 30 years’ experience of senior leadership in the USA and globally Enhanced the leadership of the Company with proven medical device experts

×